The US Department of Veteran Affairs (VA) has selected Hadlima, a biosimilar to Humira (adalimumab), as the preferred product on its National Formulary. This decision has significant implications for veterans requiring this medication, primarily by reducing treatment costs and potentially expanding access to care. Jon Martin, US commercial lead of biosimilars at Organon, discusses the benefits of this switch and the crucial role pharmacists play in educating veterans about biosimilars.
Image Credit: rh2010 – stock.adobe.com
The Impact of Hadlima’s Preferred Status on the VA Formulary
The VA’s decision to prioritize Hadlima represents a collaborative effort between the public and private sectors to enhance the affordability of essential medications. This cost reduction allows the VA to allocate resources more effectively, potentially enabling them to treat a greater number of veterans. This move aligns with the VA’s history of supporting biosimilar adoption, further solidifying their commitment to providing cost-effective, high-quality care.
Ensuring a Smooth Transition for Veterans from Humira to Hadlima
The VA has extensive experience in formulary management and transitioning patients between medications. While the process is expected to be similar to previous formulary adjustments, pharmacists and physicians will play a vital role in educating veterans about the switch to Hadlima, addressing any concerns, and explaining the benefits.
Increased Accessibility and Adherence with Hadlima
As a high-quality, large-scale healthcare system, the VA prioritizes access to cost-effective therapies. Hadlima’s inclusion on the formulary allows the VA to offer a less expensive treatment option without compromising the quality of care provided to veterans. This improved accessibility may also contribute to better treatment adherence.
Paving the Way for Future Biosimilar Adoption
The VA has consistently been a leader in embracing biosimilars, with several already holding exclusive formulary positions. This decision regarding Hadlima reinforces this leadership and sets a precedent for other healthcare systems to consider biosimilars as viable alternatives to reference products, potentially driving broader market adoption and further cost savings for patients.
The Pharmacist’s Role in the Hadlima Transition
Pharmacists have long been advocates for biosimilars and possess a deep understanding of their benefits. They are well-positioned to educate patients about biosimilars, address any misconceptions, and facilitate a seamless transition from Humira to Hadlima. Their expertise will be essential in ensuring veterans receive the necessary information and support.
Promoting Acceptance of Biosimilars among Healthcare Professionals
The VA’s adoption of Hadlima serves as a significant example for other healthcare systems and professionals. Given the VA’s scale and reach, serving nearly 9 million eligible veterans, this decision can significantly impact the broader acceptance and utilization of biosimilars. It underscores the VA’s ongoing commitment to providing veterans with access to affordable and effective treatments.
The Future of Biosimilars and Patient Savings
The availability of biosimilars like Hadlima offers significant cost savings for patients, especially those facing high copays for brand-name medications. With potential discounts of up to 85%, biosimilars present a valuable opportunity to reduce the financial burden of treatment for patients in the United States and improve access to vital medications.
Conclusion
The VA’s decision to replace Humira with Hadlima on its National Formulary represents a significant step towards improving affordability and accessibility of essential medications for veterans. Pharmacists will play a key role in educating veterans about this change and ensuring a smooth transition. This move also sets a positive example for the wider adoption of biosimilars, ultimately benefiting patients across the healthcare system. For personalized treatment plans and further information about Hadlima, consult with a healthcare professional.
